Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

ABT

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

ABT

AI Research Report

Powered by Claude

Ready to analyze ABT

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

Quant grades are available for tickers in our scored universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

whgksdhr1111@naver.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

Analyst Consensus

Buy
Based on 35 analysts
Period: 2026-04-01
26 Buy (74%)9 Hold (26%)0 Sell (0%)
Rating Distribution
Strong Buy
10
Buy
16
Hold
9
Sell
0
Strong Sell
0
Trend
2026-04
26/9/0
2026-03
25/10/0
2026-02
25/10/0
2026-01
24/11/0
📅 Earnings today Before open
NASDAQAfter-hours
ABT
$101.78
$1.09 (+1.08%)
After-hrs · vs prev close $100.69
Open
$100.53
Prev close
$100.69
Day range
$100.40 – $102.18
52W range
— – —
Mkt cap
—
P/E
—
EPS
—
Beta
—
  • Yahoo·5h ago

    Jim Cramer Says Abbot Is “Going to Have to Give Us a Couple of Reasons on the Call” to Go Higher

    Abbott Laboratories (NYSE:ABT) is among the stocks on Jim Cramer’s game plan as he shared his take on the market post Iran-U.S. ceasefire talks. Cramer called the stock “tricky,” as he commented: I also want to hear from Abbott Labs, and this is tricky, okay? Its stock’s down an astounding 20% for the year after […]

  • Yahoo·9h ago

    EHRA 2026 Studies Reveal Why False Positives Persist in AI-Equipped Implantable Cardiac Monitors

    Research identifies guideline-based interpretation gaps and signal-detection issues behind non-actionable alerts and shows how an additional cloud-based AI layer can significantly reduce clinician review burden while maintaining high sensitivityCAMBRIDGE, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Implicity, a leader in remote patient monitoring and cardiac data management solutions, today revealed new research presented at the 2026 European Heart Rhythm Association Congress (EHRA) examining why

  • SeekingAlpha·10h ago

    The Hidden Winners Inside SCHD - April 2026 Breakdown

    Schwab U.S. Dividend Equity ETF (SCHD) has outperformed in 2026, up over 11% YTD versus a flat SPY.

  • Benzinga·15h ago

    Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q1 Earnings

    Abbott Laboratories (NYSE: ABT) to report Q1 earnings on April 16, expected EPS of $1.15 and revenue of $11B. Acquired Exact Sciences, stock up 0.4%.

  • Yahoo·1d ago

    Unlocking Q1 Potential of Abbott (ABT): Exploring Wall Street Estimates for Key Metrics

    Besides Wall Street's top-and-bottom-line estimates for Abbott (ABT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.

  • Yahoo·1d ago

    Abbott Laboratories to contest damages awarded in NEC infant-formula ruling

    An Illinois court awarded $53m to four families last week and a further $17m on Friday (10 April) in the latest necrotizing enterocolitis (NEC) legal case.

  • Yahoo·1d ago

    Persian Gulf, Oil Outlooks Damp Wall Street Pre-Bell, Asia, Europe Off

    Wall Street futures pointed lower pre-bell Monday after President Donald Trump said the US will bloc

  • Finnhub·1d ago

    Illinois Jury Awards Four Families $70 Million in Verdict Against Baby Formula Manufacturer

    CHICAGO - A Cook County jury has returned a verdict of $70 million including $17 million in punitive damages against Abbott Laboratories, the manufacturer of the cow's milk-based infant feeding...

  • View all news →
⚠️
Dilution risk detected

4 offering-related filings in the last 60 filings. Latest: 424B5 on 2026-02-25. View all →

Recent insider activity

View all →
  • 4Insider transaction
    12d ago
  • 4Insider transaction
    12d ago
  • 4Insider transaction
    12d ago
  • 4Insider transaction
    12d ago
  • 4Insider transaction
    12d ago